Meeting
2021 ASCO Annual Meeting
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.
Authors
Xiaoliang Wang
Flatiron Health, New York, NY
Xiaoliang Wang , Mustafa Ascha , Tammy Green , Heather G. Lewin , Timothy N Showalter , Lori J. Goldstein , Gregory Sampang Calip , Kristen Danielle Whitaker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Access to Care
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6541)
DOI
10.1200/JCO.2021.39.15_suppl.6541
Abstract #
6541
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.
First Author: Ajay Dhakal
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim
Poster
2022 ASCO Annual Meeting
Post-recurrence survival in asymptomatic compared with symptomatic metastatic breast cancer: A multicenter retrospective study.
First Author: Sayaka Kuba
Poster
2021 ASCO Annual Meeting
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
First Author: Hans-Christian Kolberg